The mouse data is one thing but hidden in the JNM published article (sits behind a paywall) in the results section the authors note "2 participants ceased due to exceptional responses". The discussion does not elaborate. Not sure if this is an 'abscopal' response they talk up but 2/56 sounding like they were cured is significant. The report concludes with recommending a phase III (randomised controlled) trial.
- Forums
- ASX - By Stock
- NOX
- Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed
NOX
noxopharm limited
Add to My Watchlist
2.94%
!
7.0¢

Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed, page-5
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
7.0¢ |
Change
0.002(2.94%) |
Mkt cap ! $19.87M |
Open | High | Low | Value | Volume |
6.8¢ | 7.0¢ | 6.8¢ | $9.483K | 136.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 62316 | 6.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.0¢ | 169053 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 112142 | 0.066 |
1 | 20000 | 0.065 |
1 | 16393 | 0.061 |
1 | 20000 | 0.059 |
1 | 15000 | 0.058 |
Price($) | Vol. | No. |
---|---|---|
0.068 | 9184 | 1 |
0.070 | 262397 | 2 |
0.072 | 44842 | 2 |
0.080 | 100000 | 1 |
0.081 | 12345 | 1 |
Last trade - 10.13am 23/07/2025 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |